… focus on the emerging small-format ‘biologics’ from ~ 2 kDa peptide–drug conjugates to larger
~ … This, in turn has made FDCs a viable option with dosing now approaching that of ADCs. …

… a viable option with dosing regimens now approaching that of ADCs with complete, well-tolerated
tumor … Most of these small-format drug conjugates promise to overcome this due to …

… for hematological malignancies and solid tumors, and over 100 ADC candidates are …
Tackling solid tumour therapy with small-format drug conjugates. Antib Ther 2020; 3: 237–45…

… -drug conjugates (ADC) are a class of anti-cancer agents used in the treatment of selected
advanced solid tumour and hematological malignancies, … ADCs consist of a cytotoxic drug (…

… Antibody-drug conjugates (ADCs) are a rapidly expanding class … drugs to the tumor site.
As of May 2021, the US Food and … four ADCs are approved for treatment of solid tumors, …

… number of solid tumors, and GD2-directed drug conjugates may … In a recent study, we
showed that ADCs based on the … a viable alternative to full-length mAbs in drug conjugates [8,9]. …

… ADCs targeting solid tumors are currently making a satisfactory breakthrough in … , ADCs in
the advanced clinical phase are mainly directed against solid tumors (four against solid tumors…

… –drug conjugates (ADCs), in which biologically active drugs … has presented challenges for
pharmaceutical researchers. After … ADCs are approved for the treatment of solid tumors, where …

… attractive feature for the treatment of solid tumors. In the present study, we explored for the
first time Fcabs as a novel scaffold for antibody–drug conjugates (ADCs). As model, various …

… Antibody–drug conjugates (ADCs) is a fast moving class of … In contrast, another family of
small-format drug conjugates … evaluation for the treatment of solid tumors, by targeting either …